CliffBio
small molecule

OZURDEX

DEXAMETHASONE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameOZURDEX
Active ingredientDEXAMETHASONE
Strength0.7MG
Dosage formIMPLANT
RouteINTRAVITREAL
ModalitySmall molecule
FDA approvalJune 2009
Marketing statusRX

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

OZURDEX patent cliff — loss of exclusivity — | CliffBio